- Home
- XXII vs PPCB Comparison
XXII vs PPCB Comparison
Compare XXII & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XXII | PPCB |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.2M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | XXII | PPCB |
|---|---|---|
| Price | $3.45 | $0.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.0K | ★ 1.3M |
| Earning Date | 05-12-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,832,530.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $79.56 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.67 | $0.11 |
| 52 Week High | $11.37 | $10.69 |
Technical Indicators
Market Signals| Indicator | XXII | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 37.59 | 27.02 |
| Support Level | $1.52 | N/A |
| Resistance Level | $6.86 | $0.40 |
| Average True Range (ATR) | 0.23 | 0.01 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 13.22 | 5.52 |
Price Performance
Historical ComparisonAbout XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
About PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.